Increase in the Annual Number of Stored Specimens and Improvement in the Equity Ratio
First written in FY2021. 12 of 19 entries say "Advanced", first in FY2022-Q1. Latest entry: 2026-08-06.
No other company in this theme has enough history to compare yet.
- 2026-08-06WorsenedEarnings
「Equity ratio First quarter of the fiscal year ending March 2027 31.9 Fiscal year ended March 2026 33.0」
The equity ratio declined to 31.9% from 33.0% at the end of the previous consolidated fiscal year. - FY2026Increase in Stored Specimens and Decline in Equity RatioAnnual report
「Over the longer term, we aim to reach annual storage of 20,000 specimens, approximately 2.5 times the current level and equivalent to 3% of births. To achieve this target, we will further strengthen collaboration with medical institutions, promote online marketing using the web and social media, and expand real-world events nationwide.」
Annual stored specimens totaled 7,357 cord blood specimens and 5,062 umbilical cord specimens, indicating an increase toward the target of 20,000 specimens, equivalent to 3% of births. Meanwhile, the equity ratio was 33.01% on a consolidated basis and 34.94% for the filing company alone, down from 35.03% on a standalone basis in the previous fiscal year. - FY2026-H1Increase in Stored Specimens and Decline in Equity RatioAnnual report
「As a result, average revenue per customer increased compared with the former plan, while new umbilical cord storage cases rose approximately 2.1 times year on year, representing substantial growth.」
New umbilical cord storage cases rose approximately 2.1 times year on year, indicating progress in increasing stored specimens. Meanwhile, the equity ratio declined from 35.0% at the end of the previous fiscal year to 33.2%, indicating mixed progress toward the targets. - FY2025AdvancedAnnual report
「To achieve annual storage of 20,000 specimens, equivalent to a storage rate of approximately 3% of births in Japan, we will further strengthen the rollout of the new HOPECELL storage plan and marketing initiatives through both real-world and online channels.」
Annual results included 8,464 cord blood specimens and 4,745 umbilical cord specimens. The company identified the expansion of HOPECELL and both marketing channels as specific measures toward its medium-term target of 20,000 specimens and a storage rate of approximately 3%. Meanwhile, the equity ratio declined from 41.15% in the previous fiscal year to 35.03%. - FY2025-H1AdvancedAnnual report
「During the interim accounting period, we focused on real-world marketing at medical institutions, including speeches and PR activities, our primary marketing channel, as well as digital marketing through online advertising and social media, and educational activities such as seminars for the media, with the aim of achieving our medium-term management target of 20,000 specimens, equivalent to a storage rate of approximately 3% of births in Japan. As a result, we achieved record highs in all categories, including stored specimens, comprising cord blood and umbilical cord specimens, revenue and profit at every level.」
The company reaffirmed its medium-term target of 20,000 specimens, equivalent to a storage rate of approximately 3% of births in Japan, and reported record highs in all categories, including stored specimens, revenue and profit at every level. The equity ratio also rose from 41.2% at the end of the previous fiscal year to 41.4%. - FY2024-Q3AdvancedAnnual report
「During the nine months ended December 31, in-person marketing, including speeches and PR activities at medical institutions, primarily obstetric facilities, which had been restricted during the COVID-19 pandemic, recovered substantially. Together with digital marketing, including online advertising and social media, it produced synergies, resulting in a record-high number of stored specimens. The business is progressing steadily toward the company's medium-term target of a 3% storage rate as a percentage of births, corresponding to projected revenue of approximately ¥6 billion and operating profit of approximately ¥1.8 billion when achieved. Equity ratio (%) 40.6 41.1 39.6」
Steady progress toward the target of a 3% storage rate as a percentage of births, corresponding to projected revenue of approximately ¥6 billion and operating profit of approximately ¥1.8 billion when achieved, was reaffirmed. The equity ratio was 41.1%, up from 39.6% at the end of the previous fiscal year. - FY2024-Q2AdvancedAnnual report
「During the six months ended September 30, the recovery of in-person marketing, including speeches and PR activities at medical institutions, primarily obstetric facilities, which had been restricted during the COVID-19 pandemic, was substantial. Together with digital marketing, including online advertising and social media, it produced synergies, resulting in a record-high number of stored specimens. The business is progressing steadily toward the company's medium-term target of a 3% storage rate as a percentage of births, corresponding to projected revenue of approximately ¥6 billion and operating profit of approximately ¥1.8 billion when achieved.」
The company reported a record-high number of stored specimens and steady progress toward its medium-term target of a 3% storage rate as a percentage of births, corresponding to projected revenue of approximately ¥6 billion and operating profit of approximately ¥1.8 billion when achieved. The equity ratio was 40.3%, exceeding the 39.6% recorded at the end of the previous fiscal year. - FY2024-Q1AdvancedAnnual report
「Equity ratio (%) 41.3 40.5 39.6」
The equity ratio was 40.5% at the end of the first quarter, up from 39.6% at the end of the previous fiscal year. The company explained that the storage rate exceeded its plan following the launch of a service providing cultured umbilical cord tissue and conditioned medium. - FY2023AdvancedAnnual report
「To further raise our cell storage rate as a percentage of all births in Japan from approximately 3%, our medium-term management target for the fiscal year ending March 2028, equivalent to approximately 20,000 stored cord blood specimens, from approximately 1% or 7,564 specimens in the current fiscal year, we are also actively promoting new businesses using treatment opportunities involving stem cells and products generated during cell culture, such as exosomes, with a view to launching them next fiscal year.」
Annual stored specimens totaled 7,564 cord blood specimens and 2,907 umbilical cord specimens. In addition, a medium-term target was specified for a cell storage rate of approximately 3% of births in Japan and approximately 20,000 cord blood specimens for the fiscal year ending March 2028. The equity ratio declined from 40.34% at the end of the previous fiscal year to 39.55%. - FY2023-Q3RestatedAnnual report
「Equity ratio (%) 41.5 40.6 40.3」
The equity ratio was 40.6%, exceeding the 40.3% recorded at the end of the previous fiscal year. However, it declined from 40.7% in the previous quarter, and no new actual or target figures for the annual number of stored specimens were provided. - FY2023-Q2AdvancedAnnual report
「Equity ratio (%) 40.7 40.3」
The equity ratio was 40.7% at the end of the second quarter, up from 40.3% at the end of the previous fiscal year. No new actual or target figures for the annual number of stored specimens were reported. - FY2023-Q1AdvancedAnnual report
「Equity ratio (%) 42.9 41.3 40.3」
The equity ratio was 41.3% at the end of the first quarter, up 1.0 percentage point from 40.3% at the end of the previous fiscal year. No new actual or target figures for the annual number of stored specimens were reported. - FY2022AdvancedAnnual report
「As a result, against the current fiscal year's target of 7,120 cord blood specimens, actual results were 6,907 cord blood specimens and 1,511 umbilical cord specimens.」
Annual stored specimens totaled 6,907 cord blood specimens and 1,511 umbilical cord specimens. The equity ratio also rose 6.9 percentage points, from 33.40% at the end of the previous fiscal year to 40.34%. - FY2022-Q3RestatedAnnual report
「Equity ratio (%) 34.8 41.5 33.4」
The equity ratio at the end of the third quarter was 41.5%, exceeding the 33.4% recorded at the end of the previous fiscal year. However, it declined from 42.1% in the previous quarter, and no new actual or target figures for the annual number of stored specimens were provided. - FY2022-Q2RestatedAnnual report
「Equity ratio (%) 42.1 33.4」
The equity ratio was 42.1%, exceeding the 33.4% recorded at the end of the previous fiscal year. However, it declined from 42.9% at the end of the first quarter, and no new progress or target figures for the annual number of stored specimens were reported. - FY2022-Q1AdvancedAnnual report
「Equity ratio (%) 42.9 33.4」
The equity ratio rose from 33.4% at the end of the previous fiscal year to 42.9%. The increase in net assets due to a public offering and the recognition of quarterly net income, among other factors, was reported. - FY2021First statedAnnual report
「As we operate in a single segment, the cell banking business, we use the annual number of stored specimens, which corresponds to revenue-generating specimens, as a benchmark for accurately and easily assessing business conditions. We will work to expand the scale of the business by increasing the annual number of stored specimens. We will also strengthen retained earnings and raise the equity ratio to ensure stable operation of the cell banking business.」
The annual number of stored specimens and the equity ratio were explicitly identified as management indicators.